期刊
ANNUAL REVIEW OF MEDICINE
卷 61, 期 -, 页码 77-90出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.042808.171814
关键词
platelet factor 4; heparin; thrombosis; immunoassays; direct thrombin inhibitors; immune thrombocytopenia; immune-mediated thrombosis
资金
- GlaxoSmithKline
- Momenta Pharmaceuticals
- Centers for Disease Control and Prevention [U01DD000014]
- National Institutes of Health [HL081395, U54HL077878, U01HL087229, U01HL072289]
- CENTERS FOR DISEASE CONTROL AND PREVENTION [U01DD000014] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL077878, R01HL081395, U01HL087229, U01HL072289] Funding Source: NIH RePORTER
Heparin-induced thrombocytopenia (HIT) is an immune-mediated hypercoagulable disorder caused by antibodies to platelet factor 4 (PF4) and heparin. HIT develops in temporal association with heparin therapy and manifests either as an unexplained thrombocytopenia or thrombocytopenia complicated by thrombosis. The propensity for thrombosis distinguishes HIT from other common drug-induced thrombocytopenias. Diagnosing HIT in hospitalized patients is often challenging because of the frequency of heparin use, occurrence of thrombocytopenia from other causes, and development of asymptomatic PF4/heparin antibodies in patients treated with heparin. This review summarizes our current understanding of the pathogenesis, clinical features, diagnostic criteria, and management approaches in HIT
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据